Journals / Bakırköy Tıp Dergisi / 2019 / Cilt: 15 - Sayı: 3

Rare Breast Malignancies

Nadir Meme Tümörleri

Pages
232–239
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Seventy-three patients that included in the study were analyzed retrospectively in terms of age, menopausal status, family history, tumor-lymph node-metastasis stage, histological grade, hormone receptor level, human epidermal growth factor receptor2 expression, operation type and overall survival (OS).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Invasive breast cancer is a heterogeneous disease group that has different biological and pathological features, and characterized with different clinical behavior, treatment results, and consequences.
📊
Key Findings & Data:Methods: Files of 1280 breast cancer patients admitted to our center between years 2000 and 2016 were evaluated.
💡
Conclusion & Impact:Seventy-three patients that included in the study were analyzed retrospectively in terms of age, menopausal status, family history, tumor-lymph node-metastasis stage, histological grade, hormone receptor level, human epidermal growth factor receptor2 expression, operation type and overall survival (OS).
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Invasive breast cancer is a heterogeneous disease group that has different biological and pathological features, and characterized with different clinical behavior, treatment results, and consequences. The rarity of most specific neoplasies does not allow large or randomized studies to determine optimal treatment. With this study, we aimed to evaluate the clinical and pathological features and treatment options and results of rare breast carcinoma patients that followed and treated in our clinic. Methods: Files of 1280 breast cancer patients admitted to our center between years 2000 and 2016 were evaluated. From these patients, who have rare breast carcinoma subtypes were included and patients with pathological diagnosis of invasive ductal carcinoma and invasive lobular carcinoma were excluded. Seventy-three patients that included in the study were analyzed retrospectively in terms of age, menopausal status, family history, tumor-lymph node-metastasis stage, histological grade, hormone receptor level, human epidermal growth factor receptor2 expression, operation type and overall survival (OS). Results: Eight histological subtypes of breast tumors were evaluated. Significant difference wasn’t found between groups in terms of mean age of the patients. In terms of histological subtypes, the most eldest patients were in papillary group, the youngest patients were in tubular group. The mean tumor diameter was also significantly different between groups (p=0.02). The mean age of the patients diagnosed with tubular and mucinous type breast carcinomas were younger than the one reported in literature and the mean tumor diameter was also larger in these tumors. Ratio of patients diagnosed at advanced stages was high (43%). While mucinous and tubular carcinomas were the histological subtypes with the best prognosis, the shortest OS was in primary breast sarcoma and neuroendocrine carcinoma group. Conclusion: Rare breast cancers are a heterogeneous malignity group with different behavior and prognosis. Our results, except some cases, were generally concordant with the data obtained from other studies. These exceptions may be related to race, regional factors, different pathological evaluation, and environmental factors. Nevertheless, comprehensive clinical studies are required because of the rare occurrence these tumors.

Özet

Amaç: İnvaziv meme kanseri, farklı biyolojik ve patolojik özellikleri olan, farklı klinik davranış, tedaviye yanıt ve sonuç ile karakterize heterojen bir hastalık grubudur. Spesifik neoplazilerin çoğunun nadir olması, optimal tedaviyi de tanımlamak için büyük veya randomize çalışmalara izin vermez. Biz de bu çalışmada kliniğimizde takip ve tedavi edilen nadir meme karsinomlarının klinik ve patolojik özelliklerini tedavi şekillerini ve sonuçlarını değerlendirmeyi amaçladık. Yöntemler: 2000-2016 yılları arasında merkezimize meme kanseri nedeniyle başvuran 1280 hastanın dosyası incelendi. Bu çalışmaya patolojik tanısı invaziv duktal karsinoma ve invaziv lobüler karsinoma olarak tanı konan hastalar dışındaki diğer nadir meme karsinomu alt tipine sahip tüm hastalar dahil edildi. Çalışmaya dahil edilen 73 hasta; yaş, menopozal durum, aile öyküsü, tümör-lenf nodu-metastaz evresi, histolojik grade’i, hormon reseptör düzeyi, HER2 ekspresyonu, uygulanan cerrahi şekli ve ortalama sağkalım (OS) süresi açısından retrospektif olarak analiz edildi. Bulgular: Sekiz histolojik tipte meme tümörü değerlendirildi. Gruplar arasında hastaların ortalama yaşları anlamlı farklı değildi. Histolojik tip olarak en yaşlı hastalar papiller grupta, en genç hastalar tübüler gruptaydı. Gruplar arasında ortalama tümör çapı belirgin olarak farklıydı (p=0,02). Tubüler ve müsinöz tip meme karsinomlarında hastaların ortalama yaşı literatürden daha gençti ve bu tümörlerde ortalama tümör çapı da daha büyüktü. İleri evrede tanı konan hasta oranı yüksekti (%43). En iyi prognozlu histolojik tipler müsinöz ve tubüler karsinom iken en kısa OS süresi primer meme sarkomu ve nöroendokrin karsinom grubundaydı. Sonuç: Nadir meme kanserleri, farklı davranış ve prognozları olan heterojen bir malignite grubudur. Sonuçlarımız bazı olgular haricinde diğer çalışmalardan elde edilen verilerle genellikle uyumluydu. Bu istisnalar ırk, bölgesel faktörler, farklı patolojik değerlendirme ve çevresel faktörlerle ilişkili olabilir. Bununla birlikte bu tümörlerin az görülmesinden dolayı kapsamlı klinik çalışmalara ihtiyaç vardır.

🔖

Cite This Article

YILDIRIM, N., ALDEMİR, M. N., ŞİMSEK, M., BİLİCİ, M., TEKİN, S. B. (2019). Rare Breast Malignancies. Bakırköy Tıp Dergisi, Cilt: 15 - Sayı: 3, 232–239. https://ajindex.com/articles/125555

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Yerushalmi R, Hayes MM, Gelmon KA. Breast carcinoma--raretypes: review of the literatüre. Ann Oncol 2009;20:1763-70.
  2. Tavassoli FA, Devilee P. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon, France: IARC Press Breast Cancer Research 2004;6:133. Northridge ME, Rhoads GG,Wartenberg D, et al. The importance of histologic type on breast cancer survival. J Clin Epidemiol 1997;50:283-90.
  3. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badev S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95.
  4. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
  5. Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat 2008;111:541-7.
  6. Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinoma. J Clin Oncol 1999;17:1442-8.
  7. Scopsi L, Andreola S, Pilotti S, Bufalino R, Baldini MT, Testori A, et al. Mucinous carcinoma of the breast. A clinicopathologic, histochemical, and immunocytochemical study with special reference to neuroendocrine differentiation. Am J Surg Pathol 1994;18:702-11.
  8. Martinez SR, Beal SH, Canter RJ, Chen SL, Khatri VP, Bold RJ. Medullary carcinoma of the breast: a population-based perspective. Med Oncol 2011;28:738-44.
  9. Aksoy A, Odabas H, Kaya S, Bozkurt O, Degirmenci M, Topçu TO, et al. Hormone receptor status and survival of medullary breast cancer patients. A Turkish cohort. Saudi Med J 2017;38:156-62.
  10. Mateo AM, Pezzi TA, Sundermeyer M, Kelley CA, Klimberg VS, Pezzi CM. Atypical medullary carcinoma of the breast has similar prognostic factors and survival to typical medullary breast carcinoma: 3,976 cases from the National Cancer Data Base. J Surg Oncol 2016;114:533-6.
  11. Chu Z, Lin H, Liang X, Huang R, Zhan Q, Jiang J, et al. Clinicopathologic characteristics of medullary breast carcinoma: A retrospective study of 117 cases. Plos One 2014;9:e111493. Roswn P. Invasive micropapillary carcinoma. Roswn’s Breast Pathology. Philadelphia, PA. L